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ABSTRACT
Objective: Brucellosis is an important zoonotic infection having a worldwide distribution. In South East Asian developing countries like India, brucellosis 
is yet well-known but often neglected disease. Although dengue fever has a global distribution, South East Asian region together with the Western 
Pacific region represents 75% of the current global disease burden. Frequent dengue fever outbreaks have been encountered in different parts of India. 
Both brucellosis and dengue fever may present with many nonspecific symptoms. This study was designed to identify the trend of their co-infection.
Methods: The study was carried out from February 2015 to July 2016 in Eastern India. Blood samples collected from clinically suspected dengue 
fever cases were confirmed serologically by dengue specific NS1, IgM, and IgG capture ELISA methods. The confirmed dengue samples were further 
subjected to Brucella specific serological and molecular investigations.
Results: Out of 37 serologically confirmed dengue cases, 8 (21.6%) showed co-infection of brucellosis and dengue fever. Female predominance was 
observed among the co-infection cases. Most of these cases belonged to the age group 21-40 years and resided in and around Kolkata.
Conclusion: This study portrays the simultaneous acquisition of these two pathogens in a few patients. Co-infection of these two pathogens, while 
feasible, has not been accounted previously in this part of India. Thus, this report highlights the significance of studying the possibility of occurrence 
of dual infection of these two diseases and its outcome in patients with febrile illness thereby providing future scope of preventing case fatalities.
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INTRODUCTION
Brucellosis is a multisystem zoonotic disease with a broad spectrum 
of clinical manifestations. The disease can be transmitted through 
consumption of unpasteurized milk and other dairy products such as 
cheese, in close contact with infected animals, inhaling infected aerosols, 
through conjunctiva or through cuts on the skin [1]. Records of human 
brucellosis revealed human to human transmission are rare and are not 
accounted much [2]. This Gram-negative coccobacillus organism has 
several species among which four are significant pathogens in humans. 
These include Brucella melitensis, Brucella abortus, Brucella suis, and B. 
canis [3]. Infections due to B. melitensis are higher in humans followed 
by B. abortus and B. suis [4]. Brucellosis may occur as an acute or chronic 
disease [5]. Common presenting symptoms of this disease are undulant 
fever, joint and muscle pain, headache, night sweat, fatigue, and weight 
loss [6]. Dengue fever is a mosquito-borne tropical disease caused by 
the dengue virus (DENV). It is an RNA virus belonging to the genus 
Flavivirus. It has mainly four serotypes - DENV1, DENV2, DENV3, and 
DENV4. These arboviruses are transmitted by the mosquitoes - Aedes 
aegypti and Aedes albopictus [7]. Symptoms include high fever, 
headache, vomiting, abdominal pain, muscle and joint pains, and a 
characteristic skin rash. Brucellosis shares common clinical parameters 
with dengue fever in endemic areas which make their differentiation a 
diagnostic challenge to the clinicians. Previous reports of co-infection of 
these two pathogens from India are absent. The present study has been 
conducted to describe the real picture of co-infection of Brucella and 
DENV in Eastern part of India.
METHODS
The study period was 18 months from February 2015 to July 2016. 
Blood samples from clinically suspected dengue cases attending the 
outpatient (medicine) department and also from patients admitted 
to a tertiary care hospital in Kolkata, located in Eastern part of 
India, were collected. This study was approved by the Institutional 
Ethical Committee. Consent and detailed history of all patients were 
documented. Serum was separated from each blood sample using the 
standard protocols and was tested for detection of dengue NS1 antigen, 
dengue specific IgM/IgG antibody by ELISA test kits (J. Mitra & Co. Pvt. 
Ltd., New Delhi, India). Serologically confirmed dengue positive sera 
samples (IgM antibody positive was the main criterion) were further 
tested by Brucella specific serological techniques such as standard 
tube agglutination test (STAT; Tulip Diagnostics Pvt. Ltd., Goa, India), 
2 mercaptoethanol test (2 ME; Sigma-Aldrich Chemicals Pvt. Ltd., 
Bengaluru, India), Rose Bengal plate test (RBPT; IAHVB, Bengaluru, 
India), IgM and IgG ELISA (Immunolab GmbH, Germany), and also by 
Brucella genus-specific molecular test like simplex polymerase chain 
reaction (PCR) carried out in a thermal cycler (Prime, UK). For PCR 
test, DNA was extracted from the serum samples using the spin column 
technique and following the instructions provided in the QIAmp DNA 
Blood Mini Kit (Qiagen, Germany). By this PCR technique, the serum 
samples were screened for the presence of the bcsp gene which is 
present in all Brucella spp.
RESULTS
Among the 37 serologically positive dengue fever cases, eight (21.6%) 
were found positive for brucellosis. The details of the co-infection cases 
(Table 1) revealed the predominance of females among the affected 
cases. Furthermore, the common affected age group was 21-40 years 
and majority of the patients resided in and around Kolkata city. The 
co-infection cases were mostly obtained in 2015 in the month of 
September followed by the month of November. The data (Table 2) 
showed the results of the tests performed for the cases thought to be 
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co-infected by Brucella and DENV during the study period. Information 
regarding other investigations done for the dual pathogen affected 
patients is discussed below.
Case 1: After admission on the 2nd day, the patient showed no 
reactivity to dengue IgM and IgG ELISA tests. Widal test was also 
nonreactive. Platelet count was 110,000/cumm. Hemoglobin level was 
11.9 g/dl. White blood cell (WBC) count was 2600/cumm. Creatinine 
was 0.58 mg/dl. Total bilirubin was 0.3 mg/dl. Total protein was 
6.5 g/dl. On the 4th day of admission, the patient was reactive to dengue 
IgM and nonreactive to dengue IgG test. Further, the patient gave 
positive results for the Brucella specific serological tests such as STAT, 2 
ME, RBPT, and IgM ELISA.
Case 2: On the day of admission, the patient was reactive to dengue 
IgM test and nonreactive to dengue IgG test. Dual malaria antigen 
was absent. Platelet count was 135,000/cumm. Hemoglobin was 
15.7 g/dl. C-reactive protein (CRP) and alanine transaminase (ALT) 
were <6.0 mg/L and 260 U/L, respectively. WBC count was 3280/cumm. 
Creatinine was 0.71 mg/dl. Prothrombin time was 12.2 seconds. The 
patient gave positive results for Brucella specific STAT, 2 ME, and RBPT 
tests.
Case 3: On 2nd day after admission, the patient was reactive to both 
dengue IgM and IgG tests. Malaria parasite was not found. Platelet 
count was 60,000/cumm. Hemoglobin was 12.5 g/dl. WBC count was 
4010/cumm. Creatinine and urea were 0.73 mg/dl and 21 mg/dl, 
respectively. The patient showed positivity in Brucella specific STAT, 2 
ME, and RBPT tests.
Case 4: On the day of admission, the patient was found nonreactive to 
both dengue IgM and IgG ELISA tests. The patient was found reactive 
to dengue NS1 antigen on the same day. Dual malaria antigen was 
absent. Platelet count was 66,000/cumm. Hemoglobin was 10.9 g/dl. 
WBC count was 2210/cumm. CRP, ALT, and creatinine were 14.8 mg/L, 
33 U/L, and 0.63 mg/dl, respectively. On the 4th day after admission, 
the patient was found reactive to both dengue IgM and IgG antibody 
tests. The patient showed positivity in Brucella specific STAT, 2 ME, and 
RBPT tests.
Case 5: On the day of admission, the patient was found reactive to 
dengue IgM ELISA and nonreactive to dengue IgG ELISA. Platelet count 
was 194,000/cumm. The patient gave positive results for Brucella 
specific STAT, 2 ME, RBPT, and IgM ELISA tests.
Case 6: On the 3rd day after admission, the patient was found reactive 
to both dengue IgM and IgG tests. Platelet count was 120,000/cumm. 
Hemoglobin was 16.0 g/dl. WBC count was 4230/cumm. Creatinine and 
urea were 0.85 mg/dl and 9.0 mg/dl, respectively. The patient showed 
positive results for Brucella specific serological tests such as STAT, 2 ME, 
RBPT, and the infection was also confirmed by Brucella genus-specific 
PCR test.
Case 7: On the day of admission, the patient was reactive to dengue IgM 
ELISA and nonreactive to dengue IgG ELISA. Hemoglobin was 13.5 g/dl. 
WBC count was 9380/cumm. CRP and creatinine were 210 mg/L and 
0.92 mg/dl, respectively. Total bilirubin was 0.7 mg/dl. Total protein 
was 6.50 g/dl. Brucella specific tests such as STAT, 2 ME, and RBPT were 
found positive for this patient.
Case 8: After admission on the 4th day, the patient was found reactive to 
dengue IgM capture ELISA test and nonreactive to dengue IgG capture 
ELISA test. WBC count was 6250/cumm. Hemoglobin was 12.7 g/dl. 
Blood albumin was 4.02 g/dl. Brucella specific serological tests such as 
STAT, 2 ME, and IgM ELISA were found positive for this patient. Further, 
the disease was confirmed by the Brucella genus-specific PCR test.
Considering the positive serological test for dengue fever (Table 2) 
and also the positive serological and molecular tests for brucellosis 
(Table 2), these patients were diagnosed as having co-infection of 
both the pathogens. Thus, during the study tenure, we recorded eight 
confirmed cases of co-infection of Brucella and DENV.
DISCUSSION
DENV is responsible for the most frequent arthropod-borne viral infection 
worldwide. In India, the occurrence of first epidemic of this disease was 
reported from Kolkata, in 1963, which was followed by other states [8]. 
Brucellosis is one of the most frequent bacterial zoonosis throughout the 
world. In India, the prevalence of human brucellosis was first described 
almost a century back, but the actual disease burden is not established 
and the published literature shows variability. Simultaneously to the 
growth of the incidence of dengue fever, cases of bacterial co-infection in 
dengue have been increasingly reported. However, reports of co-infection 
of Brucella and DENV are very few. Till now, two studies showed this 
kind of co-infection both of which were from Saudi Arabia. Among these 
studies, the first was reported in 2006 [9] and the other was recorded in 
2010 [10]. From India, no such occurrence of this sort of dual infection 
is documented so far. Therefore, this study was done to recognize the 
simultaneous Brucella infection either in acute or chronic stage among 
the dengue fever affected patients who were admitted or attended the 
clinic of a tertiary care hospital in Eastern India. Both brucellosis and 
dengue fever present as acute febrile illness with other nonspecific 
symptoms thus creating a diagnostic dilemma for the clinicians. A high 
index of clinical suspicion coupled with appropriate diagnostic tests is 
essential to detect this kind of co-infection at an early stage. Diagnosis 
of both these diseases usually depends on serological techniques 
because of its widespread availability and ease of use. Other definitive 
diagnostic technique such as PCR for detection of Brucella spp. was also 
carried out in this study. During the study period, we found eight cases 
of Brucella and DENV co-infection and it can be said that this type of 
disease incidence is not only the first documentation from this country 
Table 1: Details of Brucella and dengue co‑infection patients
Case Number Sex Age (years) Location
1 Female 37 24 Parganas (S)
2 Male 26 Midnapore (E)
3 Female 65 Kolkata
4 Female 30 Kolkata
5 Female 26 Kolkata
6 Male 58 24 Parganas (S)
7 Male 25 Jharkhand
8 Female 12 Howrah
Table 2: Diagnostic tests done for co‑infection cases
Case Number Dengue NS1 Dengue IgM Dengue IgG STAT 2 ME RBPT Brucella IgM Brucella IgG PCR
1 - + - + + + + - -
2 - + - + + + - - -
3 - + + + + + - - -
4 + + + + + + - - -
5 - + - + + + + - -
6 - - + + + + - - +
7 - + - + + + - - -
8 - + - + + - + - +
STAT: Standard tube agglutination test, 2 ME: 2 mercaptoethanol, RBPT: Rose Bengal plate test, PCR: Polymerase chain reaction
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but also it is much higher in number than reported in previous studies. 
Hence, proper monitoring of this co-infection in this part of India can 
lead to early recognition and implementation of definitive treatment to 
patients affected by this dual infection. It was noticed (Table 2) that the 
majority of the dengue fever affected patients had DENV IgM antibodies 
which is a marker of primary dengue infection and can be detected from 
as early as 3 days to 60 days of infection. One patient had both DENV 
IgM and IgG antibodies denoting secondary dengue infection as she was 
also affected by Brucella. DENV specific IgG antibodies appear at about 
7th day, reaches peak within 2-3 weeks and persist for life [11]. Earlier 
study reported that in secondary dengue infection IgG levels remain at 
higher levels for about 30-40 days than observed in primary or past 
dengue infection, and mostly, these cases are also accompanied by 
elevation of IgM antibody titer [12]. Another patient showed positivity 
to all dengue specific serological tests done in this study. On the day of 
admission, the patient was reactive to dengue NS1 antigen ELISA test 
which can be detected from as early as 1-day post onset syndrome and 
remains positive till 18 days [13]. On the 4th day after admission, dengue 
IgM and IgG antibodies were found in that female patient. All these cases 
of dengue fever showed simultaneous positivity in one or more Brucella 
specific tests conducted in the study. It was also observed that among 
these patients, three patients had both Brucella IgM antibodies and 
DENV IgM antibodies indicating that both these diseases were in their 
acute stage. An explanation for this phenomenon can be the possible 
cross-reactivity between Brucella and DENV. However, earlier reports 
do not reveal such kind of cross-reactivity till date. Cross-reactivity of 
Brucella with other bacteria are reported [14] but no reports regarding 
cross-reactivity with viruses particularly the Flavivirus group has been 
published. On the other hand, prior reports showed that the antibodies 
from the sera of dengue fever affected patients can cross-react with 
the antibodies of other Flavivirus like Japanese encephalitis and yellow 
fever viruses [15]. Therefore, these patients can be considered as cases 
of co-infection of these two pathogens and not cross-reactivity among 
these pathogens. Although brucellosis generally proceeds toward 
chronicity [3], it was found that in this study among the dual pathogen 
infected patients, none of them suffered from chronic brucellosis as 
Brucella IgG ELISA was negative in all cases.
CONCLUSION
In this study, the simultaneous serological and molecular biological 
documentation of these two pathogens are described suggesting dual 
infection in few patients with febrile illness. This is the first report 
of this kind from the Eastern part of India. To conclude, this study 
emphasizes the need of continuous monitoring to identify co-infection 
of Brucella and DENV. Furthermore, it can be said that this type of study 
will enable the clinicians the scope to recognize the signs early and 
start proper treatment which will prevent future worsening outcome in 
mortality and morbidity rates.
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